In addition, as the immune checkpoints are often used to escape immune surveillance by cancer cells, we also explore the response of checkpoint inhibitors (e.g., PD-1, PD-L1, PD-L2, CTLA-4, LAG3, and TIM-3) and discovered that many of these genes significantly increased in the high-risk group. This evidence concerns the gene PDCD1LG2 and cancer.